Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dorzagliatin + small molecule GLP-1
- Development stage
- Unknown
- Lead developer
- Hua Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dorzagliatin + small molecule GLP-1 is a combination therapy under development by Hua Medicine for the treatment of type 2 diabetes and obesity. The combination consists of dorzagliatin (HMS5552), a first-in-class glucokinase activator (GKA), and a proprietary small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA), such as HMS-1649. Dorzagliatin acts as a glucose sensor restorer by activating glucokinase in the pancreas, liver, and intestine, thereby improving insulin secretion and glucose metabolism. The small molecule GLP-1RA component enhances glucose-dependent insulin secretion, inhibits glucagon release, and slows gastric emptying, while also providing weight loss benefits through appetite suppression. This oral combination therapy is designed to provide a synergistic approach to metabolic control by targeting multiple physiological pathways involved in glucose homeostasis and energy balance.
- Other names
- dorzagliatin + small molecule GLP-1HMS5552 + HMS-1649dorzagliatin + small molecule GLP-1 receptor agonist
02
Targets
GCK (Glucokinase)
Beyond the preview
Go deeper on dorzagliatin + small molecule GLP-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dorzagliatin + small molecule GLP-1.